Biosimilars/News
Cipla launches first etanercept ‘similar biologic’ in India
India-based generics manufacturer Cipla announced on 17 April 2013 the launch of its ‘similar biologic’ product Etacept, the first ‘similar biologic’ of etanercept in India.
Lonza not backing out on biosimilars
Lonza has made a statement refuting reports that the Switzerland-based company was considering backing out of its biosimilars joint venture with Israeli generics giant Teva Pharmaceutical Industries (Teva).
Amgen’s biosimilar plans
Amgen was one of the first companies to recognize the potential of modern biotechnology and this has made it the world’s largest independent biotechnology firm.
Lonza/Teva biosimilar pact in jeopardy
Switzerland-based API producer and custom manufacturing organization Lonza is reviewing whether it is still worth investing in its joint venture for biosimilars with Israeli generics giant Teva Pharmaceutical Industries (Teva).
Sandoz’s biosimilar rituximab on track
The development of a biosimilar version of Rituxan (rituximab) is proceeding as planned, Sandoz’s Global Head, Mr Jeff George told Bloomberg.
When will the US biosimilars pathway be used
FDA Commissioner Margaret Hamburg presented the latest statistics on the US biosimilar pathway during a speech at the Massachusetts Biotechnology Council’s (MassBio) Annual Meeting on 15 March 2013.
Greece says no to automatic substitution of biologicals
Greece’s Medicines Agency (National Organization for Medicines, Ethnikos Organismos Farmakon, EOF) released a document on 13 March 2013 recommending against automatic substitution/interchangeability of reference biologicals and their biosimilars.
Japan approves second biosimilar G-CSF
Japan has granted regulatory approval to a second biosimilar granulocyte colony-stimulating factor (G-CSF).
XBiotech moves into biosimilars
US-based biotech company XBiotech announced on 26 February 2013 that the company would be expanding its portfolio to include biosimilars.
Mylan and Biocon to partner on insulin products
Generics giant Mylan announced on 13 February 2013 that it had entered into an agreement with India-based Biocon to develop and market Biocon’s biosimilar versions of three insulin analogue products.
